Carbylan BioSurgery, a developer of device/drug combination products, has released Hydros-TA joint therapy (Hydros-TA) and Hydros positive COR1.0 clinical trial results.
Hydros-TA is a next generation viscosupplement/steroid single-injection combination product comprised of bacterially derived hyaluronic acid (HA) and gets modified to form biodegradable hydrogel beads.
The multi-center, double-blinded study is designed to assess the safety and effectiveness of a single injection of Hydros-TA or Hydros compared to Synvisc-One.
The study data showed superior pain relief and improved function in patients with pain from knee osteoarthritis using Hydros-TA when compared to Synvisc-One.
Lawson Health Research Institute Beryl & Richard Ivey Research Chair COR1.0 trial principal investigator Robert Petrella said it combines two well known treatment therapies, viscosupplementation and intra-articular corticosteroid, and provides the patient with a single, fast-acting, long-lasting therapy which appears to be effective.